Hookipa Pharma INC

HOOKIPA Pharma Inc. stockholders have approved the sale of certain assets to Gilead Sciences, Inc. and the subsequent liquidation and dissolution of the company.

HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister its securities, leading to the company's dissolution and liquidation after an asset sale to Gilead Sciences, Inc.

Hookipa Pharma Inc. announces an asset purchase agreement with Gilead Sciences for its HB-400 and HB-500 programs, leading to a planned dissolution of the company.

HOOKIPA Pharma has decided not to pursue the acquisition of Poolbeg Pharma, as announced on February 20, 2025.

HOOKIPA Pharma is seeking court validation for actions taken at its 2022 and 2023 annual meetings due to incorrectly set record dates, which could impact the validity of issued shares and corporate actions.

HOOKIPA Pharma and Poolbeg Pharma have provided an update on their non-binding discussions regarding a potential acquisition of Poolbeg by HOOKIPA, with Gilead Sciences indicating its intention to support the deal.

HOOKIPA Pharma's Q1 2025 revenue decreased significantly due to the termination of the Roche collaboration, while the company focuses on strategic alternatives and cost-saving measures.

HOOKIPA Pharma's Q3 2024 results reflect a strategic refocus, restructuring efforts, and continued development of its immuno-oncology pipeline, with a net loss of $13.8 million.

HOOKIPA Pharma Inc. announced its second quarter 2024 results, highlighting a strategic shift towards its oncology programs and a restructuring plan.

HOOKIPA Pharma's Q1 2024 results show a significant increase in revenue due to collaboration agreements and a strategic restructuring to focus on key programs.

HOOKIPA Pharma Inc. filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

HOOKIPA Pharma Inc. reports its 10-K filing for the fiscal year ended December 31, 2024, highlighting pipeline progress, financial results, and a strategic restructuring plan.

HOOKIPA Pharma Inc.'s document outlines the details of its registered securities, including common stock, Class A common stock, and preferred stock, under the Securities Exchange Act of 1934.

Malte Peters, CEO of HOOKIPA Pharma Inc., executed a sale of 25,172 shares of common stock at a weighted average price of $0.8217 per share.

HOOKIPA Pharma Inc.'s CEO, Malte Peters, sold 29,176 shares of common stock at $0.92 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

HOOKIPA Pharma Inc.'s EVP and CFO, Mary Theresa Coelho, sold 13,609 shares of common stock at $0.92 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Mary Theresa Coelho, EVP and CFO of Hookipa Pharma Inc., reports the acquisition of restricted stock units (RSUs) that will vest over the next two years.

CEO of Hookipa Pharma, Malte Peters, reports acquisition of common stock through a restricted stock unit grant.

Director Sean A. Cassidy acquired 9,800 stock options in Hookipa Pharma Inc. on July 22, 2024.

HOOKIPA Pharma Inc. is seeking stockholder approval for the sale of its Hepatitis B and HIV programs to Gilead Sciences for up to $10 million, followed by the company's liquidation and dissolution, with an estimated per-share distribution of $1.28 to $1.72 to stockholders.

HOOKIPA Pharma Inc. announced an agreement to sell its HB-400 and HB-500 programs to Gilead Sciences, Inc. for up to $10 million, with plans to dissolve the company and distribute remaining cash to stockholders following the transaction.

Hookipa Pharma Inc. has entered into an agreement to sell its HB-400 and HB-500 programs to Gilead Sciences for up to $10 million and intends to dissolve the company pending stockholder approval.

HOOKIPA Pharma and Poolbeg Pharma provide an update on their non-binding discussions regarding a potential acquisition of Poolbeg by HOOKIPA, including Gilead's intended participation in a concurrent fundraise.

HOOKIPA Pharma and Poolbeg Pharma provide an update on their potential combination, with Gilead Sciences indicating support and HOOKIPA announcing a $30 million+ private placement fundraise.

HOOKIPA Pharma and Poolbeg Pharma are in preliminary talks for HOOKIPA to acquire Poolbeg in an all-share transaction, aiming to create a strong biopharmaceutical company.

Sofinnova Capital VI FCPR and its affiliates have reported a decrease in their beneficial ownership of HOOKIPA Pharma Inc. to 2.6%, primarily due to an increase in the issuer's outstanding shares from a June 2023 public offering.

EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has filed an amended Schedule 13G disclosing a passive beneficial ownership of 4.0% in HOOKIPA Pharma Inc.'s common stock as of December 31, 2024.